Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders.

Haematologica - 1 Dec 2008

Theocharides Alexandre, Passweg Jakob R, Medinger Michael, Looser Renate, Li Sai, Hao-Shen Hui, Buser Andreas S, Gratwohl Alois, Tichelli André, Skoda Radek C

Abstract excerpt

In a retrospective single center study we determined the time course of the JAK2-V617F or JAK2 exon 12 allele burden in DNA from purified granulocytes from 48 patients with myeloproliferative disorders. The percentage of change between the first and last sample in JAK2-V617F positive patients wit...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aged, 80 and over
Share to Alleles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Granulocytes

Share to Hydroxyurea

Share to Janus Kinase 2

Share to Myeloproliferative Disorders

Share to Young Adult

Source

Identifiers

PMID: 18790796
DOI: 10.3324/haematol.13074

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18790796-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders.PMID 18790796Read ↗

Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden.Semantic proximity Read ↗

Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.Semantic proximity Read ↗

JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatmentSemantic proximity Read ↗

Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemiaSemantic proximity Read ↗

Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia veraSemantic proximity Read ↗

JAK2V617F allele burden is associated with transformation to myelofibrosis.Semantic proximity Read ↗

Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders.Semantic proximity Read ↗

Influence of JAK2 46/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasms.Semantic proximity Read ↗

JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse.Semantic proximity Read ↗

JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms.Semantic proximity Read ↗

JAK2 exon 14 skipping in patients with primary myelofibrosis: a minor splice variant modulated by the JAK2-V617F allele burden.Semantic proximity Read ↗

The JAK2V617F mutation in normal individuals takes place in differentiating cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.